Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. Drug Pipeline

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. maintains a substantial clinical development portfolio, with 42 trials registered since 2008, including 30 currently active studies. Clinical activity is heavily concentrated in oncology, which accounts for 80% of active programs (24 trials). The remaining active trials are distributed across immunology (2 trials), respiratory (1 trial), and metabolic diseases (1 trial). Within oncology, the leading indications by active trial count are breast cancer (6 active, 3 in Phase 3), advanced solid tumors (5 active), colorectal cancer (3 active, 1 in Phase 3), multiple myeloma (2 active), and non-small cell lung cancer (2 active). The pipeline includes 16 active Phase 1 trials, 13 active Phase 2 trials, and 5 active Phase 3 trials. The relatively high number of Phase 3 trials in breast cancer and colorectal cancer suggests a potential for near-term clinical catalysts.